​

Stoke Therapeutics (STOK) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Stoke Therapeutics Revenue Highlights

Latest Revenue (Y)

$36.55M

Latest Revenue (Q)

$13.82M

Main Segment (Y)

License

Stoke Therapeutics Revenue by Period

Stoke Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$36.55M316.34%
2023-12-31$8.78M-29.22%
2022-12-31$12.40M100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

Stoke Therapeutics generated $36.55M in revenue during NA 2024, up 316.34% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Stoke Therapeutics Revenue by Quarter

DateRevenueChange
2025-06-30$13.82M-91.29%
2025-03-31$158.57M601.20%
2024-12-31$22.61M362.08%
2024-09-30$4.89M1.30%
2024-06-30$4.83M14.59%
2024-03-31$4.22M50.46%
2023-12-31$2.80M-15.30%
2023-09-30$3.31M-233.33%
2023-06-30$-2.48M-148.16%
2023-03-31$5.15M57.60%
2022-12-31$3.27M12.53%
2022-09-30$2.90M-10.09%
2022-06-30$3.23M7.70%
2022-03-31$3.00M100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Stoke Therapeutics generated $13.82M in revenue during Q2 2025, up -91.29% compared to the previous quarter, and up 327.73% compared to the same period a year ago.

Stoke Therapeutics Revenue Breakdown

Stoke Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
License$29.40M
Service$7.20M

Stoke Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (80.33%), and Service (19.67%).

Stoke Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
SRPTSarepta Therapeutics$1.90B$744.86M
LMATLeMaitre Vascular$219.86M$64.23M
OCULOcular Therapeutix$63.46M$13.39M
STOKStoke Therapeutics$36.55M$13.82M
LQDALiquidia$14.00M$3.12M
CLDXCelldex Therapeutics$7.02M$695.00K
ETNB89bio--
VRDNViridian Therapeutics--
VERAVera Therapeutics--
BHVNBiohaven--
CELCCelcuity--

STOK Revenue FAQ

What is Stoke Therapeutics’s yearly revenue?

Stoke Therapeutics's yearly revenue for 2024 was $36.56M, representing an increase of 316.34% compared to 2023. The company's yearly revenue for 2023 was $8.78M, representing a decrease of -29.22% compared to 2022. STOK's yearly revenue for 2022 was $12.4M, representing an increase of 100.00% compared to 2021.

What is Stoke Therapeutics’s quarterly revenue?

Stoke Therapeutics's quarterly revenue for Q2 2025 was $13.82M, a -91.29% decrease from the previous quarter (Q1 2025), and a 186.01% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $158.57M, a 601.20% increase from the previous quarter (Q4 2024), and a 3661.12% increase year-over-year (Q1 2024). STOK's quarterly revenue for Q4 2024 was $22.61M, a 362.08% increase from the previous quarter (Q3 2024), and a 707.07% increase year-over-year (Q4 2023).

What is Stoke Therapeutics’s revenue growth rate?

Stoke Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 194.68%, and for the last 5 years (2020-2024) was 0%.

What are Stoke Therapeutics’s revenue streams?

Stoke Therapeutics's revenue streams in c 24 are License, and Service. License generated $29.4M in revenue, accounting 80.33% of the company's total revenue Service generated $7.2M in revenue, accounting 19.67% of the company's total revenue

What is Stoke Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Stoke Therapeutics was License. This segment made a revenue of $29.4M, representing 80.33% of the company's total revenue.